Study guide

8.3 Blood Labeling and Administration Techniques

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

8.3 Blood Labeling and Administration Techniques

Key Takeaways Explain This Topic AI

RBC labeling methods rank by efficiency: in vitro UltraTag® (highest) > modified in vivo > pure in vivo (most free Tc risk)

WBC labeling uses In-111 oxine or Tc-99m HMPAO with sterile cell separation, incubation, washing, and reinjection of the same patient’s cells only

Labeling efficiency = (cell-bound activity / total activity) × 100%; know assay of pellet vs supernatant or equivalent method

Administration routes include IV, oral, inhaled, and intrathecal; technique choices include bolus vs infusion under aseptic conditions

Critical identity checks (two identifiers, labels, written directive match) prevent wrong-patient administration of blood products and therapeutic doses

Last updated: August 2026

8.3 Blood Labeling and Administration Techniques

Quick Answer: RBCs are labeled in vivo , modified in vivo , or in vitro (UltraTag®) for MUGA and GI bleeding. WBCs are labeled with In-111 oxine or Tc-99m HMPAO for infection imaging. Always calculate labeling efficiency , use aseptic technique, and perform two-identifier patient/sample checks before reinjection.

Wrong-patient cell reinjection is a never-event. Exam stems hide ID failures, free Tc after poor RBC labels, or low WBC efficiency.

RBC Labeling Methods

Goal: bind Tc-99m to hemoglobin so activity stays in the blood pool . Stannous ion (Sn²⁺) pretinning reduces technetium for intracellular binding. Inadequate tin or oxidizing interference leaves free pertechnetate in stomach, thyroid, and salivary glands .

Method Sequence (teaching) Relative efficiency Clinical notes

In vivo Inject PYP/stannous IV → wait ~20–30 min → inject Tc-99m pertechnetate IV Lowest (~60–80%; variable) Simplest; more free Tc

Modified in vivo Stannous PYP IV → wait → withdraw blood into syringe with Tc-99m (± anticoagulant) → incubate → reinject Intermediate (~85–90%) Balances convenience and quality

In vitro (UltraTag®) Draw blood → kit tin/oxidant steps → add Tc-99m → incubate → wash/assay → reinject Highest (often ≥95–98% ) Preferred for GI bleed / critical quality

Interfering factors: recent transfusion , residual line heparin , oxidizing drugs, wrong kit order, or short incubation. Do not inject pertechnetate before tin in pure in vivo labeling. Uses: MUGA/ERNA, GI bleeding, hemangioma blood-pool—typical adult activity often ~20–30 mCi when well labeled.

WBC Labeling: In-111 Oxine and Tc-99m HMPAO

Labeled leukocytes localize at sites of infection/inflammation (sterile inflammation can still light up—specificity has limits). Maintain closed sterile technique throughout; cell damage from rough handling lowers both viability and labeling efficiency.

Shared Workflow Principles

Verify identity of patient and collection tubes before phlebotomy.

Draw adequate venous blood into anticoagulant (ACD or heparin per protocol).

Sediment / centrifuge to separate leukocyte-rich fraction; remove RBCs as required.

Incubate cells with lipophilic chelate ( In-111 oxine or Tc-99m exametazime/HMPAO ).

Wash to remove unbound activity; assay bound vs free.

Resuspend and reinject IV only into the same patient after dual ID check.

Image at agent-appropriate times (In-111 often 4–24 h; Tc-99m HMPAO earlier windows).

  • Feature In-111 oxine WBCs Tc-99m HMPAO WBCs
  • Half-life / energy 67 h; 171 & 245 keV 6 h; 140 keV
  • Imaging window Delayed imaging convenient Same-day imaging; earlier bowel excretion issues
  • Typical activity (adult order) ~ 0.3–0.5 mCi ~ 5–10 mCi
  • Cell handling Oxine is toxic in excess—controlled incubation Fresh HMPAO critical; kit stability limits
  • Strength Better delayed distribution studies Higher photon flux, lower patient dose concept

Low efficiency → free activity artifacts and poor contrast. Plasma proteins compete with oxine—washing technique matters. Neutropenia may yield inadequate cells; process one patient at a time on the bench.

Labeling Efficiency Calculation Labeling efficiency (%) = Activity in cells (bound) Activity in cells + Activity in supernatant (free) × 100 \text{Labeling efficiency (\%)} = \frac{\text{Activity in cells (bound)}}{\text{Activity in cells} + \text{Activity in supernatant (free)}} \times 100 Labeling efficiency (%) = Activity in cells + Activity in supernatant (free) Activity in cells (bound) ​ × 100

Assay both fractions in a dose calibrator (geometry per SOP). Document efficiency before injection. Below the departmental limit → do not reinject without authorized radiopharmacy/user disposition (relabel or reschedule). Example: cells 9.2 mCi, supernatant 0.8 mCi → 9.2/10.0 × 100% = 92% .

Routes of Administration

Route Examples Technique notes

Intravenous Most diagnostic RPs; labeled cells; Lu-177; Ra-223 Patent IV; avoid infiltration (hot pocket, incomplete dose)

Oral I-131/I-123 NaI capsules or liquid NPO status; verify swallow; liquid spill control

Inhaled Xe-133 gas; Tc-99m DTPA aerosol; Technegas (where used) Closed system, exhaust/trap, room contamination control

  • Intrathecal In-111 DTPA cisternography Sterile spinal access by credentialed operator; strict asepsis
  • Intra-arterial Y-90 microspheres IR suite; residual activity assay
  • Interstitial / intradermal Lymphoscintigraphy Small-volume technique; never give a lymph dose as an IV push

Route errors are high-severity: an oral therapy capsule is not an IV push, and a filtered colloid lymph dose is not a liver-spleen IV dose. Always read the order, label, and written directive together before the needle or capsule reaches the patient.

Bolus for rapid first-pass or fixed regadenoson timing; infusion for adenosine, dipyridamole, dobutamine, amino acids—use controlled delivery and stay with the patient. Asepsis: scrub hubs, sterile technique for cell labels/intrathecal/therapy; labeled blood is autologous yet still biohazardous and radioactive.

Critical Patient-Sample Identity Checks

Before collection , labeling , and reinjection : (1) two identifiers matched to wristband, requisition, and labels; (2) label tubes/syringes at bedside immediately; (3) worksheet matches name, ID, RP, activity, route, time, and written directive when required; (4) second-person verify therapies/blood products per policy; (5) any mismatch → stop .

  • Admin step Why
  • Assay in calibrator Confirm prescribed activity
  • Check expiration/calibration Decay and kit stability
  • Confirm route and site Oral ≠ IV; lymph ≠ IV
  • Flush/survey as SOP Residual activity, spills
  • Document lot, activity, time, site Legal/QC record

Infiltration: stop, mark site, estimate residual, notify authorized user, survey, manage site per isotope policy, and decide if remaining activity meets the study need.

  • Need Prefer
  • Highest RBC quality (GI bleed) UltraTag in vitro
  • Delayed infection imaging In-111 WBCs
  • Same-day infection imaging Tc-99m HMPAO WBCs
  • Any autologous cells Same-patient reinjection + dual ID

Master the efficiency formula , three RBC methods , WBC step chain , and identity culture —these four themes dominate CNMT administration items more than obscure kit brand names.